Simon Shaw, PhD, BSc

Rigel Pharmaceuticals, Inc.
South San Francisco, CA, United States

Simon Shaw is responsible for medicinal chemistry at Rigel Pharmaceuticals. In over ten years at Rigel, he has contributed to immunology, metabolism and CNS targeted projects leading to four clinical candidates.

Presentation(s):

• 1329: R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.